Using mathematical models to integrate PD, PK, and disease progression. is now accepted by the FDA. MIDD allows developers to simulate a Phase III trial using virtual patients, predicting optimal dosing for elderly, pediatric, or renally-impaired populations without exposing them to risk.
: Medicinal chemists and pharmacologists refine these hits to improve their pharmacodynamics (how well they bind to the target) and pharmacokinetics (how the body absorbs and processes them). 3. Safety in the Lab (Preclinical Research) pharmacology in drug discovery and development
While chemists synthesize molecules and clinicians treat patients, pharmacologists are the translators. They answer the fundamental questions that turn a chemical compound into a medicine: Is it safe? Does it work? How does the body handle it? Using mathematical models to integrate PD, PK, and
PK is the study of a drug's journey through the body, which dictates whether a promising lab compound can actually be used as a pill or an injection. Pharmacologists track this via the framework: : Medicinal chemists and pharmacologists refine these hits
Before you can design a key, you need to understand the lock. In pharmacological terms, the "lock" is the biological target—usually a receptor, enzyme, ion channel, or nucleic acid—responsible for a disease process.
— summarized as "what the body does to the drug" — describes the journey of a drug from the moment it is administered until it is eliminated from the body. This process is typically broken down into four key stages, often referred to as ADME: